Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

3 Months Ended

Oct. 31, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	15,822			—			—			—		$	15,822
Product revenues		—		$	8,002			—			—			8,002
Royalty and license fee income		—			1,000			—			—			1,000
		15,822			9,002			—			—			24,824
Operating expenses:
Cost of clinical laboratory services		10,130			—			—			—			10,130
Cost of product revenues		—			3,695			—			—			3,695
Research and development		—			548		$	243			—			791
Selling, general and administrative		5,066			3,150			—		$	2,069			10,285
Provision for uncollectible accounts receivable		530			11			—			—			541
Legal fee expense		91			1			—			2,374			2,466
Total operating expenses		15,817			7,405			243			4,443			27,908

Operating income (loss)		5			1,597			(243	)		(4,443	)		(3,084	)

Other income (expense)
Interest		(27	)		2			—			(44	)		(69	)
Other		2			(8	)		—			25			19
Foreign exchange loss		—			(472	)		—			—			(472	)
Income (loss) before income taxes	$	(20	)	$	1,119		$	(243	)	$	(4,462	)	$	(3,606	)

Depreciation and amortization included above	$	357		$	560		$	1		$	20		$	938

Share-based compensation included in above:
Cost of clinical laboratory services	$	1			—			—			—		$	1
Research and development		—		$	1			—			—			1
Selling, general and administrative		9			—			—		$	87			96
Total	$	10		$	1			—		$	87		$	98

Capital expenditures	$	254		$	10		$	—		$	—		$	264

Three months ended October 31, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,860			—		—			—		$	14,860
Product revenues		—		$	7,663		—			—			7,663
Royalty and license fee income		—			1,611		—			—			1,611
		14,860			9,274		—			—			24,134
Operating expenses:
Cost of clinical laboratory services		9,709			—		—			—			9,709
Cost of product revenues		—			3,846		—			—			3,846
Research and development		11			526	$	280			—			817
Selling, general and administrative		5,050			3,495		—		$	1,984			10,529
Provision for uncollectible accounts receivable		844			28		—			—			872
Legal fee expense		148			22		—			1,211			1,381
Total operating expenses		15,762			7,917		280			3,195			27,154

Operating income (loss)		(902	)		1,357		(280	)		(3,195	)		(3,020	)

Other income (expense)
Interest		(11	)		5		—			(56	)		(62	)
Other		18			27		—			16			61
Foreign exchange gain		—			297		—			—			297
Income (loss) before income taxes	$	(895	)	$	1,686	$	(280	)	$	(3,235	)	$	(2,724	)

Depreciation and amortization included above	$	355		$	641	$	4		$	25		$	1,025

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—		—			—		$	2
Research and development		—			1		—			—			1
Selling, general and administrative		10		$	4		—		$	86			100
Total	$	12		$	5		—		$	86		$	103

Capital expenditures	$	259		$	75	$	—		$	—		$	334

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details